5HJP

Identification of LXRbeta selective agonists for the treatment of Alzheimer's Disease


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.6 Å
  • R-Value Free: 0.283 
  • R-Value Work: 0.236 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Identification and in Vivo Evaluation of Liver X Receptor beta-Selective Agonists for the Potential Treatment of Alzheimer's Disease.

Stachel, S.J.Zerbinatti, C.Rudd, M.T.Cosden, M.Suon, S.Nanda, K.K.Wessner, K.DiMuzio, J.Maxwell, J.Wu, Z.Uslaner, J.M.Michener, M.S.Szczerba, P.Brnardic, E.Rada, V.Kim, Y.Meissner, R.Wuelfing, P.Yuan, Y.Ballard, J.Holahan, M.Klein, D.J.Lu, J.Fradera, X.Parthasarathy, G.Uebele, V.N.Chen, Z.Li, Y.Li, J.Cooke, A.J.Bennett, D.J.Bilodeau, M.T.Renger, J.

(2016) J.Med.Chem. 59: 3489-3498

  • DOI: 10.1021/acs.jmedchem.6b00176
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Herein, we describe the development of a functionally selective liver X receptor β (LXRβ) agonist series optimized for Emax selectivity, solubility, and physical properties to allow efficacy and safety studies in vivo. Compound 9 showed central pharm ...

    Herein, we describe the development of a functionally selective liver X receptor β (LXRβ) agonist series optimized for Emax selectivity, solubility, and physical properties to allow efficacy and safety studies in vivo. Compound 9 showed central pharmacodynamic effects in rodent models, evidenced by statistically significant increases in apolipoprotein E (apoE) and ATP-binding cassette transporter levels in the brain, along with a greatly improved peripheral lipid safety profile when compared to those of full dual agonists. These findings were replicated by subchronic dosing studies in non-human primates, where cerebrospinal fluid levels of apoE and amyloid-β peptides were increased concomitantly with an improved peripheral lipid profile relative to that of nonselective compounds. These results suggest that optimization of LXR agonists for Emax selectivity may have the potential to circumvent the adverse lipid-related effects of hepatic LXR activity.


    Organizational Affiliation

    WuXi AppTec Company, Ltd. , Shanghai 200131, P. R. China.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Retinoic acid receptor RXR-beta
A, C
254Homo sapiensMutation(s): 0 
Gene Names: RXRB (NR2B2)
Find proteins for P28702 (Homo sapiens)
Go to Gene View: RXRB
Go to UniProtKB:  P28702
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Oxysterols receptor LXR-beta
B, D
264Homo sapiensMutation(s): 4 
Gene Names: NR1H2 (LXRB, NER, UNR)
Find proteins for P55055 (Homo sapiens)
Go to Gene View: NR1H2
Go to UniProtKB:  P55055
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
PEG
Query on PEG

Download SDF File 
Download CCD File 
B, C
DI(HYDROXYETHYL)ETHER
C4 H10 O3
MTHSVFCYNBDYFN-UHFFFAOYSA-N
 Ligand Interaction
668
Query on 668

Download SDF File 
Download CCD File 
B, D
2-chloro-4-{1'-[(2R)-2-hydroxy-3-methyl-2-(trifluoromethyl)butanoyl]-4,4'-bipiperidin-1-yl}-N,N-dimethylbenzamide
C25 H35 Cl F3 N3 O3
POYRTHYMXFSQBJ-XMMPIXPASA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.6 Å
  • R-Value Free: 0.283 
  • R-Value Work: 0.236 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 66.770α = 90.00
b = 106.028β = 90.00
c = 139.818γ = 90.00
Software Package:
Software NamePurpose
PDB_EXTRACTdata extraction
HKL-2000data reduction
PHASERphasing
HKL-2000data scaling
BUSTER-TNTrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2016-04-06
    Type: Initial release
  • Version 1.1: 2016-04-20
    Type: Database references
  • Version 1.2: 2016-04-27
    Type: Database references